Skyrizi for the treatment of moderate to severe plaque psoriasis, approved by European Commission
The European Commission ( EC ) has approved Skyrizi ( Risankizumab ) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Skyrizi ( 150 mg ) is approved to be administered by two subcutaneous injections every 12 weeks following two initiation doses at week 0 and week 4.
In clinical studies, Skyrizi has demonstrated high rates of skin clearance at 16 weeks and this clearance was durable at one year ( 52 weeks ).
Skyrizi has received EC approval based on results from four pivotal phase 3 studies, ultIMMa-1, ultIMMa-2, IMMvent and IMMhance evaluating more than 2,000 patients with moderate to severe plaque psoriasis.
Across all four studies, the co-primary endpoints were at least a 90% improvement in the Psoriasis Area and Severity Index ( PASI 90 ) and a static Physician Global Assessment ( sPGA ) score of clear or almost clear ( sPGA 0/1 ) at week 16.
In the ultIMMa-1 and ultIMMa-2 studies, Skyrizi met the co-primary endpoints of sPGA 0/1 and PASI 90 at week 16 ( p less than 0.001 ).
After 16 weeks of treatment, 88% ( ultIMMa-1 ) and 84% ( ultIMMa-2 ) of Skyrizi patients achieved sPGA 0/1 and 75% of patients receiving Skyrizi in both studies achieved PASI 90.
An integrated analysis of patients who received Skyrizi in the ultIMMa-1 and ultIMMa-2 studies showed that, of patients who achieved PASI 90 with Skyrizi at week 16, 88% of these patients maintained PASI 90 with Skyrizi at one year ( 52 weeks ).
Of patients who achieved PASI 100 with Skyrizi at week 16, 80% maintained PASI 100 with Skyrizi at one year ( 52 weeks ).
Skyrizi demonstrated superiority versus Adalimumab ( Humira ) in the IMMvent study, with 72% of patients achieving PASI 90 compared to 47% of patients treated with Adalimumab at week 16 ( p less than 0.001 ).
Following re-randomization at week 16, 66% of patients who started on Adalimumab and switched to Skyrizi achieved PASI 90, compared to 21% who continued on Adalimumab at week 44 (p less than 0.001 ).
The co-primary endpoints of sPGA 0/1 and PASI 90 at week 16 were met ( p less than 0.001 ).
Results from IMMhance showed that, among people receiving Skyrizi who achieved clear or almost clear skin ( sPGA 0/1 ) response at week 28 and were re-randomized to continue Skyrizi ( n=111 ), 87% maintained this response at week 52 compared to 61% re-randomized to withdraw ( n=225 ).
The co-primary endpoints of sPGA 0/1 at week 16 and week 52 were met ( p less than 0.001 ).
Skyriz was also reported to improve health-related quality of life in phase 3 studies. In ultIMMa-1 and ultIMMa-2, significantly more patients treated with Skyriz self-reported a DLQI ( Dermatology Life Quality Index ) score of 0 or 1 ( 75% in ultIMMa-1 and 71% in ultIMMa-2 ) compared with Ustekinumab ( 47% in ultIMMa-1 and 44% in ultIMMa-2 ) at one year ( p less than 0.001 ).
The most frequently reported adverse reactions were upper respiratory infections, which occurred in 13% of patients.
Common adverse reactions ( frequency defined as greater than or equal to 1/100 events to less than 1/10 ) included tinea infections, headache, pruritus, fatigue and injection site reactions. ( Xagena )
Source: Abbvie, 2019
FDA has approved Emgality, the first treatment for episodic cluster headache that reduces the frequency of attacks
The FDA ( U.S. Food and Drug Administration ) has approved Emgality ( Galcanezumab-gnlm; Galcanezumab ) solution for injection for...
The Food and Drug Administration ( FDA ) has approved Nubeqa ( Darolutamide ) for non-metastatic castration-resistant prostate cancer. Approval was...
Relapsed and refractory multiple myeloma: European Commission has approved Empliciti plus Pomalidomide and low-dose Dexamethasone
The European Commission ( EC ) has approved Empliciti ( Elotuzumab ) plus Pomalidomide and low-dose Dexamethasone ( EPd )...
Direct-acting antivirals reduce risk of premature mortality and liver cancer for patients with chronic hepatitis C
The first prospective, longitudinal study investigating treatment of chronic hepatitis C with direct-acting antivirals finds that the treatment is associated...
Satralizumab, an anti-IL-6 receptor monoclonal antibody, reduces relapse risk for neuromyelitis optica spectrum disorder
Full pivotal phase III SAkuraStar study results for Satralizumab as a monotherapy for neuromyelitis optica spectrum disorder ( NMOSD ),...
FDA has approved treatment for patients with endometrial carcinoma: Lenvima in combination with Keytruda
The FDA ( U.S. Food and Drug Administration ) has announced Project Orbis, an initiative of the FDA Oncology Center...
The European Commission has granted marketing authorization in the European Union ( EU ) for the precision oncology treatment Vitrakvi...
Adults and children with all genotypes of hepatitis C and compensated cirrhosis: Mavyret shortens duration of treatment to eight weeks, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has expanded the approval of Mavyret ( Glecaprevir and Pibrentasvir )...
FDA has approved Ofev, first treatment for patients with interstitial lung disease associated with systemic sclerosis or scleroderma
The FDA ( U.S. Food and Drug Administration ) has approved Ofev ( Nintedanib ) capsules to slow the rate...
Standard methods to detect NTRK fusions in daily practice and clinical research: ESMO recommendations
NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most...